infigratinib (Truseltiq) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CCN1CCN(CC1)c2ccc(Nc3cc(ncn3)N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)cc2
  • InChIKey: QADPYRIHXKWUSV-UHFFFAOYSA-N
  • Mol. Mass: 560.49
  • ALogP: 5.35
  • ChEMBL Molecule:
    bgj-398  
More Chemistry

Pharmacology

Alternative names

3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | bgj398 | bgj-398 | infigratinib | nvp-bgj398

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (23)

Approved Indications (1)


 

Cholangiocarcinoma (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (23)


 

Achondroplasia (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Cholangiocarcinoma (Phase 3)

Colonic Neoplasms (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 1/Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Early Phase 1)

Glioma (Phase 2)

Hematologic Neoplasms (Phase 2)

Intestinal Neoplasms (Phase 1/Phase 2)

Lung Neoplasms (Phase 1)

Melanoma (Phase 2)

Mutation (Phase 3)

Nasopharyngeal Neoplasms (Phase 2)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1/Phase 2)

Papillomavirus Infections (Phase 2)

Receptors, Fibroblast Growth Factor (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 1)

Uterine Cervical Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 27
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue